{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:09:18Z","timestamp":1788761358864,"version":"build-2803163510"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced soft tissue sarcoma (STS) is a group of rare and heterogeneous malignancies, requiring better therapeutic strategies. Pazopanib, a widely used second-line treatment, has been suggested to exert immunomodulatory effects, which may be relevant for enhancing response. Specifically, pazopanib reduces immunosuppressive cells like myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) while enhancing the function of dendritic cells, T cells, and NK effectors. Based on this knowledge, we hypothesized that proteins involved in immunomodulation could serve as predictive biomarkers of response to pazopanib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore immune-related biomarkers of prognosis and pazopanib response in advanced soft tissue sarcoma using paired pre- and post-treatment tumour samples and complementary preclinical models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      Exploratory translational study integrating differential gene expression profiling of clinical specimens with in silico prognostic evaluation and\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      functional assays in soft tissue sarcoma cell lines treated with pazopanib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HTG transcriptome-direct profiling was performed on paired FFPE tumour samples from pazopanib-treated patients, followed by bioinformatic identification of differentially expressed genes and survival correlations, and subsequent validation of candidate biomarkers, at RNA and protein levels in sarcoma cell lines exposed to pazopanib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Using HTG transcriptomics, we identified 38 differentially expressed genes in post-pazopanib STS samples. Among them,\n                      <jats:italic toggle=\"yes\">SERPINE1<\/jats:italic>\n                      was the most consistent dynamic biomarker, showing a 4.19-fold increase (FDR = 0.016) and correlating with poor survival (progression-free survival (PFS), p = 0.033; disease-free survival (DFS), p = 0.004).\n                      <jats:italic toggle=\"yes\">In vitro<\/jats:italic>\n                      , SERPINE1 upregulation was observed in STS cell lines CP0024 (24h, 1.47-fold; 48h, 1.71-fold), ICP059 (48h, 1.15-fold), and 93T449 (72h, 2.29-fold), with earlier expression in more sensitive cell lines. Protein validation confirmed these results after 48h of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our results support\n                      <jats:italic toggle=\"yes\">SERPINE1<\/jats:italic>\n                      as a biomarker for poor prognosis and suggest its role as an exploratory, hypothesis-generating candidate marker for pazopanib response, warranting further validation in larger cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261474856","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:50:16Z","timestamp":1785545416000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers of prognosis and pazopanib response in soft tissue sarcoma: An exploratory analysis"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5642-3796","authenticated-orcid":false,"given":"Jose L.","family":"Mondaza-Hernandez","sequence":"first","affiliation":[{"name":"Group of Advanced Therapies and Biomarkers in Sarcoma, Research Health Institute of Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD)"},{"name":"Medical Oncology Department, University Hospital General of Villalba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Amian-Ruiz","sequence":"additional","affiliation":[{"name":"Molecular Biology of Cancer, Instituto de Biomedicina de Sevilla (IBiS; Hospital Universitario Virgen del Roc\u00edo \/ CSIC \/ Universidad de Sevilla)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Antonio Cordero Varela","sequence":"additional","affiliation":[{"name":"Molecular Biology of Cancer, Instituto de Biomedicina de Sevilla (IBiS; Hospital Universitario Virgen del Roc\u00edo \/ CSIC \/ Universidad de Sevilla)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Augusta","family":"Carrera-Haro","sequence":"additional","affiliation":[{"name":"Group of Advanced Therapies and Biomarkers in Sarcoma, Research Health Institute of Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD)"},{"name":"Medical Oncology Department, University Hospital General of Villalba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Celeste","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Group of Advanced Therapies and Biomarkers in Sarcoma, Research Health Institute of Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD)"},{"name":"Medical Oncology Department, University Hospital General of Villalba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lopez-Alvarez","sequence":"additional","affiliation":[{"name":"Molecular Biology of Cancer, Instituto de Biomedicina de Sevilla (IBiS; Hospital Universitario Virgen del Roc\u00edo \/ CSIC \/ Universidad de Sevilla)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Villar","sequence":"additional","affiliation":[{"name":"University of St Andrews"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa","family":"Ramos","sequence":"additional","affiliation":[{"name":"Hospital Universitari Son Espases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valverde","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-1641","authenticated-orcid":false,"given":"Josefina","family":"Cruz","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Canarias"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martinez-Trufero","sequence":"additional","affiliation":[{"name":"Hospital Universitario Miguel Servet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Diaz-Beveridge","sequence":"additional","affiliation":[{"name":"La Fe University and Polytechnic Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Hindi","sequence":"additional","affiliation":[{"name":"Group of Advanced Therapies and Biomarkers in Sarcoma, Research Health Institute of Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD)"},{"name":"Medical Oncology Department, University Hospital General of Villalba"},{"name":"Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fernandez-Serra","sequence":"additional","affiliation":[{"name":"Instituto Valenciano de Oncolog\u00eda (IVO) Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Lopez-Guerrero","sequence":"additional","affiliation":[{"name":"Instituto Valenciano de Oncolog\u00eda (IVO) Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Moura","sequence":"additional","affiliation":[{"name":"Molecular Biology of Cancer, Instituto de Biomedicina de Sevilla (IBiS; Hospital Universitario Virgen del Roc\u00edo \/ CSIC \/ Universidad de Sevilla)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-6916","authenticated-orcid":false,"given":"Javier","family":"Martin-Broto","sequence":"additional","affiliation":[{"name":"Group of Advanced Therapies and Biomarkers in Sarcoma, Research Health Institute of Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD)"},{"name":"Medical Oncology Department, University Hospital General of Villalba"},{"name":"Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23252"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00475"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.200"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0499"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1707"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/264360"},{"issue":"12","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1007\/s12094-023-03221-6","article-title":"Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study","volume":"25","author":"Gutierrez-Sainz L","year":"2023","unstructured":"Gutierrez-Sainz L, Martinez-Fdez S, Pedregosa-Barbas J, et al. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023; 25(12): 3519\u20133526. https:\/\/doi.org\/10.1007\/s12094-023-03221-6","journal-title":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3283622d3a"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx423.001"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0594"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.014"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1189"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.651"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10344"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111651"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.7091"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201700237RR"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051071"},{"issue":"5","key":"e_1_3_8_24_2","first-page":"1875","article-title":"Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA","volume":"44","author":"Zhang Q","year":"2020","unstructured":"Zhang Q, Lei L, Jing D. Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA. Oncology reports 2020; 44(5): 1875\u20131884. https:\/\/doi.org\/10.3892\/or.2020.7770","journal-title":"Oncology reports"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.304554"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.10.027"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-150516"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.5211"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-1234"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43924-x"},{"issue":"7","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/1055-9965.EPI-14-0035","article-title":"Urinary protein biomarker panel for the detection of recurrent bladder cancer","volume":"23","author":"Rosser CJ","year":"2014","unstructured":"Rosser CJ, Chang M, Dai Y, et al. Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2014; 23(7): 1340\u20131345. https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-0035","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108994"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00413-1"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3064"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00978"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001561"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30153-6"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0871"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02278-9"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30081-0"},{"issue":"10","key":"e_1_3_8_41_2","article-title":"Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis","volume":"30","author":"Dias ESD","year":"2025","unstructured":"Dias ESD, Pernomian LS, Fernandes M, et al. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis. Oncologist 2025; 30(10).","journal-title":"Oncologist"},{"key":"e_1_3_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.10.082"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1487610"},{"key":"e_1_3_8_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0278-0"},{"key":"e_1_3_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.01.011"},{"key":"e_1_3_8_46_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2015-0012OC"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-4134"},{"key":"e_1_3_8_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14727"}],"updated-by":[{"DOI":"10.1177\/17588359261487896","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000}}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261474856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261474856","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261474856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:58:44Z","timestamp":1788760724000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261474856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":47,"alternative-id":["10.1177\/17588359261474856"],"URL":"https:\/\/doi.org\/10.1177\/17588359261474856","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"17588359261474856"}}